Patents by Inventor Suzanne D. Conzen

Suzanne D. Conzen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
    Patent number: 11883417
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: January 30, 2024
    Assignee: The University of Chicago
    Inventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
  • METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS AND ANTI-ANDROGEN RECEPTOR THERAPY AND ANTI-ANDROGEN RECEPTOR THERAPY
    Publication number: 20230218634
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: December 23, 2022
    Publication date: July 13, 2023
    Applicant: University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists and anti-androgen receptor therapy
    Patent number: 11564932
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: January 31, 2023
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER
    Publication number: 20220133746
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Application
    Filed: January 18, 2022
    Publication date: May 5, 2022
    Inventors: Deng PAN, Masha KOCHERGINSKY, Suzanne D. CONZEN
  • Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
    Patent number: 11234990
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: February 1, 2022
    Assignee: The University of Chicago
    Inventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
  • METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20200330482
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 22, 2020
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists after anticancer therapy
    Patent number: 10729699
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: August 4, 2020
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER
    Publication number: 20200030344
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Application
    Filed: October 8, 2019
    Publication date: January 30, 2020
    Inventors: Deng PAN, Masha KOCHERGINSKY, Suzanne D. CONZEN
  • Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
    Patent number: 10441596
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 15, 2019
    Assignee: The University of Chicago
    Inventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
  • METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20190255069
    Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: April 3, 2019
    Publication date: August 22, 2019
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists
    Patent number: 10300076
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 28, 2019
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • METHODS AND COMPOSITIONS FOR TREATING BREAST AND PROSTATE CANCER
    Publication number: 20190134004
    Abstract: The current disclosure relates to combination treatments for breast cancers such as TNBC and for prostate cancers. Embodiments concern methods, compositions, and apparatuses for treating breast cancer and prostate cancer patients. Aspects relate to a method of inhibiting proliferation of glucocorticoid receptor positive (GR+) breast or prostate cancer cells comprising administering to the cells an effective amount of a BET inhibitor in combination with one or both of a chemotherapeutic agent and a glucocorticoid receptor modulator.
    Type: Application
    Filed: June 16, 2017
    Publication date: May 9, 2019
    Inventors: Suzanne D. Conzen, Russell Szmulewitz
  • Methods and compositions related to Hsp90 inhibitors and breast cancer
    Patent number: 10071130
    Abstract: Embodiments of the invention are directed to methods of treating cancer cells, particularly breast cancer cells, such as chemo-resistant cells, with an Hsp90 inhibitor and an anticancer agent or compound such as chemotherapy.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 11, 2018
    Assignee: The University of Chicago
    Inventor: Suzanne D. Conzen
  • METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROST A TE CANCER
    Publication number: 20180036318
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: September 14, 2017
    Publication date: February 8, 2018
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Method of treatment for prostate cancer with androgen receptor antagonists and glucocorticoid receptor antagonists
    Patent number: 9801893
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: October 31, 2017
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER
    Publication number: 20170182066
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 29, 2017
    Inventors: Deng PAN, Masha KOCHERGINSKY, Suzanne D. CONZEN
  • Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
    Patent number: 9623032
    Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: April 18, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Deng Pan, Masha Kocherginsky, Suzanne D. Conzen
  • METHODS AND COMPOSITIONS RELATED TO HSP90 INHIBITORS AND BREAST CANCER
    Publication number: 20160317601
    Abstract: Embodiments of the invention are directed to methods of treating cancer cells, particularly breast cancer cells, such as chemo-resistant cells, with an Hsp90 inhibitor and an anticancer agent or compound such as chemotherapy.
    Type: Application
    Filed: December 12, 2014
    Publication date: November 3, 2016
    Inventor: Suzanne D. Conzen
  • Methods and Compositions Related to Glucocorticoid Receptor Antagonism and Prostate Cancer
    Publication number: 20160151388
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Application
    Filed: February 2, 2016
    Publication date: June 2, 2016
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists
    Patent number: 9289436
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: March 22, 2016
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen